Serna Bio
serna.bioMake every gene druggable with AI-designed RNA-targeting small molecules
Health & Wellnessdrug-discoveryrnasmall-moleculesaibiotechmachine-learningtherapeutics
About
Serna Bio is a drug discovery company that uses AI and machine learning to design small molecules targeting RNA rather than proteins. Their platform leverages synthetic biology, ML, and multiplexed screening to modulate translation and splicing for hard-to-drug targets. They aim to expand the druggable genome by treating RNA as a therapeutic target for diseases with high unmet medical need.
Problem
Many disease-causing proteins are considered 'undruggable', leaving a vast portion of the genome inaccessible to conventional drug development.
For
pharmaceutical researchers and biotech partners seeking RNA-targeted therapies
How it works
Serna Bio's AI platform rationally designs selective small molecules that target RNA structures involved in translation and splicing, bypassing the need to target proteins directly.
Business model
unknown
Status
unknown
Company
Serna Bio